Sun Pharmaceutical Industries, an international, integrated, speciality pharmaceutical company, today said that the company's FY16 revenue could remain flat or show a decline over FY15 as the company expects to incur certain integration charges in order to generate long-term synergies from the Sun Pharma-Ranbaxy merger.

In addition to the revenue impact, the company expects that profits may also be adversely impacted due to certain expenses/charges arising out of integration as well as remedial actions.

"Our target for the synergy benefits from the Ranbaxy acquisition has increased by 15-20% as compared to our original target of USD 250 million by FY18," the company said.

Sun Pharmaceuticals will continue to allocate significant resources to R&D in order to strengthen the specialty pipeline including patented products and complex generics.

As a part of Current Good Manufacturing Practices (cGMP) process and in order to address the cGMP deviations at its Halol facility, the company has undertaken various remedial measures. These remedial measures have resulted in supply constraints for some of the products. The company is working towards the fulfilment of the requirements of the US consent decree.

Shares of the company gained Rs 0.45, or 0.05%, to settle at Rs 946.80. The total volume of shares traded was 82,788 at the BSE (Monday).